drugset / Trial / NCT03889366

Relative Bioavailability of NXP001 Compared to Emend® in Healthy Volunteers

NCT03889366

Phase 1 Completed 12 enrolled Nuformix Technologies Limited
RandomizedCrossoverOpen-labelOther

Summary

This study will compare the relative bioavailability of both an oral capsule formulation and an oral suspension formulation of NXP001 to Emend® in healthy male volunteers in the fasted state.

Timeline

Start
2019-03-20
Primary completion
2019-04-15
Completion
2019-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Aprepitant Other / unclassified 125 mg Oral

Indications

No indication recorded.